Does PRRT with standard activities of 177Luoctreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: Insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-6

  Sabet, Amir ^a   Nagarajah, James ^b   Dogan, Ahmet Semih ^a   Biersack, Hans Jürgen ^a   Sabet, Amin ^a   Guhlke, Stefan ^a   Ezziddin, Samer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 68; OCTREOTATE LU 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN TISSUE; LIVER PARENCHYMA; MALE; METASTASIS; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SPLEEN;

EID: 84891440987     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-82     Document Type: Article

References (34)

1. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20(8):716-731.
2. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27(3):273-282.
3. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24(4):389-427.
4. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, Van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010, 17(1):R53-R73. doi:ERC-09-0078 10.1677/ERC-09-0078.
5. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U: Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003, 5(1):42-48. doi:S1536163203000386.
6. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48(4):508-518. doi:48/4/508.
7. Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, Biersack HJ, Guhlke S, Reichmann K: Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med 2012, 37(6):e141-e147. doi:10.1097/RLU.0b013e31823926e5 00003072-201206000-00030.
8. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011, 29(17):2416-2423. doi:JCO.2010.33.7873 10.1200/JCO.2010.33.7873.
9. Kwekkeboom DJ, De Herder WW, Van Eijck CH, Kam BL, Van Essen M, Teunissen JJ, Krenning EP: Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010, 40(2):78-88. doi:S0001-2998(09)00102-0 10.1053/j.semnuclmed.2009.10.004.
10. Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, Brockmann H, Willinek W, Wardelmann E, Biersack HJ, Ahmadzadehfar H: Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011, 38(3):459-466. doi:10.1007/s00259-010-1610-2.
11. Ezziddin S, Sabet A, Heinemann F, Yong Hing CJ, Ahmadzadehfar H, Guhlke S, Höller T, Willinek W, Boy C, Biersack HJ: Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J NuclMed 2011, 52(8):1197-1203. doi:jnumed.111.090373 10.2967/jnumed.111.090373.
12. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3] octreotate. Eur J Nucl Med Mol Imaging 2003, 30(3):417-422. doi:10.1007/s00259-002-1050-8.
13. Kwekkeboom DJ, Mueller Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005, 46(Suppl 1):62S-66S. doi:46/1_suppl/62S.
14. Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, Bodei L, Garaboldi L, Bartolomei M, Paganelli G: Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 2013, 97(4):347-354. doi:000348394 10.1159/ 000348394.
15. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G: Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011, 38(12):2125-2135. doi:10.1007/ s00259-011-1902-1.
16. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SW, Krenning EP: Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995, 36(4):623-627.
17. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC: Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006, 47(3):502-511. doi:47/3/502.
18. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S: Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009, 94(2):654-661. doi:jc.2008-1919 10.1210/jc.2008-1919.
19. Forrer F, Valkema R, Kwekkeboom DJ, De Jong M, Krenning EP: Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21(1):111-129. doi:S1521-690X(07)00008-5 10.1016/j.beem.2007.01.007.
20. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos Kudla B, de Herder WW, Plöckinger U, Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009, 90(2):220-226. doi:000225951 10.1159/000225951.
21. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Horsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013, 40(5):800-816. doi:10.1007/s00259-012-2330-6.
22. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP: Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003, 30(6):917-920. doi:10.1007/s00259-003-1142-0.
23. Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M: The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003, 30(2):312-315. doi:10.1007/s00259-002-1054-4.
24. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, De Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP: Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005, 23(12):2754-2762. doi:23/12/2754 10.1200/JCO.2005.08.066.
25. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, Rösch F: Processing of generator-produced 68Ga for medical application. J Nucl Med 2007, 48(10):1741-1748. doi:jnumed.107.040378 10.2967/jnumed.107.040378.
26. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC: Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009, 50(6):936-941. doi:jnumed.108.061457 10.2967/jnumed.108.061457.
27. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, Müller-Brand J, Hofmann M: 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005, 32(6):724. doi:10.1007/s00259-004-1697-4.
28. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E: Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab 2010, 95(5):2343-2350. doi:jc.2009-2487 10.1210/jc.2009-2487.
29. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, Stroh T: Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007, 148(5):2095-2105. doi:en.2006-1266 10.1210/en.2006-1266.
30. Haug AR, Rominger A, Mustafa M, Auernhammer C, Goke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M: Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011, 52(11):1679-1683. doi:jnumed.111.089276 10.2967/jnumed.111.089276.
31. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergström M, Långström B: In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol 2010, 37(3):265-275. doi:S0969-8051(09)00288-1 10.1016/j.nucmedbio.2009.11.008.
32. Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, Bihl H: Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993, 20(5):431-433.
33. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ: Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTATyr3-octreotide positron emission tomography and 123Imetaiodobenzylguanidine: a clarification. Eur J Nucl Med Mol Imaging 2012, 39(3):543. doi:10.1007/s00259-011-1962-2.
34. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S: 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011, 38(7):1224-1236. doi:10.1007/s00259-011-1760-x.